**opening soon**

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu 08/18
Brain Cancer Clinical Trials

**THERAPEUTIC 1ST LINE**

**BRAIN CANCER**

**THERAPEUTIC 2ND LINE**

**UCI 16-55**
Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma (Bota)

**ALLIANCE-A071601**
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas (Bota)

**NRG BN003**
Ph III Trial of observation versus irradiation for a gross totally resected grade II meningioma (Kong)

**UCI 17-115**
Phase II Trial Of AV-GBM-1 As An Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation In Patients With Newly Diagnosed Glioblastoma (Bota)

**UCI 17-88**
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with RT and TMZ in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (Bota)

**UCI 14-58**
Ph1, Multicenter, Open-Label, Dose Escalation, Combination Study Of Marizomib And Bevacizumab In Bevacizumab-Naïve Subjects With Gradeiv MG Followed By Ph2 Studies Of Single Agent MRZ And Combination MRZ And Bevacizumab, And Ph1 Dose-Escalation Study Of Enterally-Administered MRZ With Bevacizumab. (Bota)

**UCI 16-56**
Ph II Study of Optune in Bevacizumab-Naïve Subjects w/ Recurrent WHO grade III Malignant Astrocytoma (Bota)

**RTOG 3503**
Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma (Kong)

**ECOG-EAY131**
**Some Cohorts Suspended**
**Molecular Analysis for Therapy Choice – MATCH** (Bota)

**SWOG S1609**
*Some cohorts suspended*
Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors – DART (Bota)

**UCI 16-22**
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Efomithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy (Bota)

**UCI 17-35**
Ph II Trial of DSP-7888 Dosing Emulsion Combo w/ Bev vs Bev Alone for Glioblastoma (Kong)

**ALLIANCE A071401**
*SUSPENDED*
Phase II Trial of SMO/ACT/NF2 Inhibitors in Progressive Meningiomas with SMO/ACT/NF2 Mutations (Bota)

**UCI 13-14**
*SUSPENDED*
Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671 + GM-CSF + Cyclophosphamide) + Bevacizumab vs. (Placebo Injection + Placebo pill) + Bevacizumab in treatment of recurrent/progressive GBM & gliosarcoma patients (WHO grade IV malignant gliomas) (Bota)

**UCI 15-35**
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent GBM or Anaplastic Astrocytoma (Bota)

**UCI 17-115**
Phase II Trial Of AV-GBM-1 As An Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation In Patients With Newly Diagnosed Glioblastoma (Bota)

**ECOG-EAY131**
**Some Cohorts Suspended**
**Molecular Analysis for Therapy Choice – MATCH** (Bota)

**SWOG S1609**
*Some cohorts suspended*
Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors – DART (Bota)

**UCI 16-22**
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Efomithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy (Bota)

**UCI 17-35**
Ph II Trial of DSP-7888 Dosing Emulsion Combo w/ Bev vs Bev Alone for Glioblastoma (Kong)

**ALLIANCE A071401**
*SUSPENDED*
Phase II Trial of SMO/ACT/NF2 Inhibitors in Progressive Meningiomas with SMO/ACT/NF2 Mutations (Bota)

**UCI 13-14**
*SUSPENDED*
Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671 + GM-CSF + Cyclophosphamide) + Bevacizumab vs. (Placebo Injection + Placebo pill) + Bevacizumab in treatment of recurrent/progressive GBM & gliosarcoma patients (WHO grade IV malignant gliomas) (Bota)

**UCI 15-35**
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent GBM or Anaplastic Astrocytoma (Bota)

**ECOG-EAY131**
**Some Cohorts Suspended**
**Molecular Analysis for Therapy Choice – MATCH** (Bota)

**SWOG S1609**
*Some cohorts suspended*
Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors – DART (Bota)

**UCI 16-22**
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Efomithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy (Bota)

**UCI 17-35**
Ph II Trial of DSP-7888 Dosing Emulsion Combo w/ Bev vs Bev Alone for Glioblastoma (Kong)

**ALLIANCE A071401**
*SUSPENDED*
Phase II Trial of SMO/ACT/NF2 Inhibitors in Progressive Meningiomas with SMO/ACT/NF2 Mutations (Bota)

**UCI 13-14**
*SUSPENDED*
Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671 + GM-CSF + Cyclophosphamide) + Bevacizumab vs. (Placebo Injection + Placebo pill) + Bevacizumab in treatment of recurrent/progressive GBM & gliosarcoma patients (WHO grade IV malignant gliomas) (Bota)

**UCI 15-35**
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent GBM or Anaplastic Astrocytoma (Bota)

**ECOG-EAY131**
**Some Cohorts Suspended**
**Molecular Analysis for Therapy Choice – MATCH** (Bota)

**SWOG S1609**
*Some cohorts suspended*
Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors – DART (Bota)

**UCI 16-22**
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Efomithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy (Bota)

**UCI 17-35**
Ph II Trial of DSP-7888 Dosing Emulsion Combo w/ Bev vs Bev Alone for Glioblastoma (Kong)

**ALLIANCE A071401**
*SUSPENDED*
Phase II Trial of SMO/ACT/NF2 Inhibitors in Progressive Meningiomas with SMO/ACT/NF2 Mutations (Bota)

**UCI 13-14**
*SUSPENDED*
Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671 + GM-CSF + Cyclophosphamide) + Bevacizumab vs. (Placebo Injection + Placebo pill) + Bevacizumab in treatment of recurrent/progressive GBM & gliosarcoma patients (WHO grade IV malignant gliomas) (Bota)

**UCI 15-35**
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent GBM or Anaplastic Astrocytoma (Bota)

**opening soon**